Neurological diseases are the foremost cause of ill health and disability worldwide. Open Access Government offers an overview of the prevalence of these conditions.
Neurological diseases are the foremost cause of ill health and disability worldwide. Open Access Government offers an overview of the prevalence of these conditions.
Yesterday on World Parkinson's Day in the Journal of Parkinson's Disease, researchers revealed the potential environmental origins of Parkinson's disease.
We spoke with Parkinson’s UK, an organisation dedicated to funding important research and supporting those affected by Parkinson’s, about the prevalence, impact, and management of the condition.
A group of researchers around the globe have created a portable, non-invasive device capable of identifying biomarkers associated with Alzheimer's and Parkinson's disease.
A team of neuroscientists, neurosurgeons and engineers have created a speech prosthesis that can interoperate a person's brain signals and convert them into speech.
In a groundbreaking collaboration, the Accelerated Capability Environment (ACE) has teamed up with the NHS's AI Skunkworks to harness AI to diagnose Parkinsons with unprecedented speed.
Digital health platforms offer vast potential for enhancing the lives of PD patients and caregivers. A study in the Journal of Nutrition Education and Behavior emphasises their role in improving healthcare services.
Professor of Neurology Thomas Gasser, JPND’s Scientific Advisory Board Chair and Director of the Department of Neurodegenerative Diseases, shares in an interview JPND’s innovative research and collaboration efforts in the universal race against Alzheimer’s and Parkinson’s diseases.
Jay Sibbitts, Prof Dr Stefan H. Bossmann and Prof Dr Christopher T. Culbertson, from Kansas State University, Department of Chemistry in the U.S., underline microfluidic detection of intracellular nitric oxide levels.
Dr Gerry Morrow shares his thoughts on the current state of play when it comes to the early diagnosis of neurodegenerative disorders, and asks the questions, can we screen, and should we screen?
A new study published in the Movement Disorders journal, has paved the way for more research into identifying markers of progression for patients in the early stages of Parkinson’s disease
